North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-01-05 Brentuximab vedotin

Brentuximab vedotin Adcetris®
Formulary
  • 50mg powder for concentrate for solution for infusion
  • Approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of CD30-positive Hodgkin lymphoma in patients:
    • if they have already had autologous stem cell transplant
    • if they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable. CDF
  • Approved for the treatment of CD30-positive cutaneous T-cell lymphoma in line with NICE
  • Approved in combination with cyclophosphamide, doxorubicin and prednisone for untreated systmic anaplastic large cell lymphoma in adults in line with NICE

 

Link  NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Link  NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma

Cytotoxic Drug  Red View adult BNF  View SPC online  View childrens BNF  HCD